Chemical formula: C₁₀H₁₇N₃S Molecular mass: 211.327 g/mol PubChem compound: 119570
Pramipexole is a dopamine agonist that binds with high selectivity and specificity to the D2 subfamily of dopamine receptors of which it has a preferential affinity to D3 receptors, and has full intrinsic activity. Pramipexole alleviates parkinsonian motor deficits by stimulation of dopamine receptors in the striatum. Animal studies have shown that pramipexole inhibits dopamine synthesis, release, and turnover.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N04BC05 | Pramipexole | N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BC Dopamine agonists |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| MIRAPEX Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| MIRAPEXIN Tablet / Prolonged-release tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Pramipexole is an active ingredient of these brands:
United States (US)
Australia (AU)Austria (AT)Brazil (BR)
Canada (CA)
Cyprus (CY)Ecuador (EC)Estonia (EE)Germany (DE)Ireland (IE)Israel (IL)
Italy (IT)
Lithuania (LT)Mexico (MX)
Netherlands (NL)New Zealand (NZ)
Poland (PL)Romania (RO)Singapore (SG)
South Africa (ZA)Tunisia (TN)
Turkey (TR)
United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
